Content uploaded by Sofia Sigra Stein
Author content
All content in this area was uploaded by Sofia Sigra Stein on May 17, 2023
Content may be subject to copyright.
Content uploaded by Eva Hesselmark
Author content
All content in this area was uploaded by Eva Hesselmark on Apr 05, 2019
Content may be subject to copyright.
Contents lists available at ScienceDirect
Neuroscience and Biobehavioral Reviews
journal homepage: www.elsevier.com/locate/neubiorev
Treatment of PANDAS and PANS: a systematic review
Sofia Sigra
a,b,1
, Eva Hesselmark
c,1,⁎
, Susanne Bejerot
a,b,c
a
School of Medical Sciences, Örebro University, Örebro, Sweden
b
University Health Care Research Center, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
c
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
ARTICLE INFO
Keywords:
Pediatric autoimmune neuropsychiatric
disorders associated with streptococcal
infections
PANDAS
Pediatric acute-onset neuropsychiatric
syndrome
PANS
PITAND
Childhood acute neuropsychiatric symptoms
CANS
Obsessive-compulsive disorder
OCD
Obsessive-compulsive symptoms
Treatment
Therapy
Systematic review
ABSTRACT
Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are a
subtype of acute-onset obsessive-compulsive disorder (OCD) thought to be caused by an autoimmune response to
group A streptococcal infection. Based on this proposed pathophysiology, alternative treatments for acute-onset
OCD have been introduced, including antibiotics and immunomodulatory interventions. However, the literature
on treatment of PANDAS is diverse, and clinical consensus regarding optimal treatment strategy is lacking. We
conducted a systematic review of articles in PubMed, Cochrane Library, and Scopus that addressed treatment for
PANDAS and related disorders. Twelve research studies involving the following treatments met inclusion cri-
teria: penicillin, azithromycin, intravenous immunoglobulin, plasma exchange, tonsillectomy, cognitive beha-
vior therapy, NSAID and corticosteroids. In addition, 65 case reports in which patients received im-
munomodulatory treatments, antibiotics, and/or psychotropics were identified. We determined that rigorously
conducted research regarding treatments for PANDAS is scarce, and published studies have a high risk of bias.
Further research is needed in which promising treatment strategies for PANDAS and other variants of OCD with
proposed autoimmune etiology are rigorously investigated.
1. Introduction
1.1. Potential autoimmune etiology of acute-onset OCD
The first 50 cases of a subtype of pediatric obsessive compulsive
disorder (OCD) with acute onset of symptoms and episodic course were
described by Swedo et al. (1998); these authors coined the term
PANDAS, or “pediatric autoimmune neuropsychiatric disorders asso-
ciated with streptococcal infections.”OCD is characterized by obsessive
thoughts and compulsive rituals. OCD has an estimated lifetime pre-
valence of 2.3% and is associated with substantial comorbidity (Ruscio
et al., 2010). Among children, OCD is a common psychiatric illness
(Stewart et al., 2004), and early-onset OCD is associated with high fa-
milial load (Browne et al., 2015) and often with tic disorders (do
Rosario-Campos et al., 2005). The etiology of OCD is unknown, but
some evidence suggests that certain cases of OCD may be autoimmune
in nature or triggered by streptococcal infection (Perez-Vigil et al.,
2016;Orlovska et al., 2017).
The pathogenesis of PANDAS is thought to be similar to that of
Sydenham’s chorea, which is also triggered by streptococcal infections
(Swedo et al., 1989;Swedo et al., 1993;Swedo et al., 1998). Specifi-
cally, antibodies raised in response to infection with group A β-hemo-
lytic Streptococcus (GABHS) cross-react with autoantigens in the basal
ganglia and cortical structures and yield the motor and behavioral ab-
normalities associated with PANDAS (Aron et al., 1965;Giedd et al.,
1995;Husby et al., 1976).
Patients with a clinical picture similar to PANDAS but with a non-
streptococcal infectious trigger are described as having PITAND, or
“pediatric infection-triggered autoimmune neuropsychiatric disorders”
(Allen et al., 1995). The term “childhood acute neuropsychiatric
symptoms (CANS)”was proposed as a broader term for patients with
PANDAS symptoms unaccompanied by GABHS infection (Singer et al.,
2012). The term “pediatric acute-onset neuropsychiatric syndrome”
(PANS) was suggested to describe children with acute-onset OCD or
eating disorders in combination with multiple psychiatric or neurolo-
gical symptoms (Swedo et al., 2012). Diagnostic criteria for PANDAS,
https://doi.org/10.1016/j.neubiorev.2018.01.001
Received 17 August 2017; Received in revised form 10 November 2017; Accepted 1 January 2018
⁎
Corresponding author at: Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute CAP Research Centre, Gävlegatan 22 B 8tr, 113 30, Stockholm
Sweden.
1
These authors contributed equally.
E-mail address: eva.hesselmark@ki.se (E. Hesselmark).
Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
Available online 06 January 2018
0149-7634/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
PANS, CANS, and PITAND are summarized in Table 1. All of these
clinical entities involve recurrent episodic acute exacerbations of tics or
obsessive-compulsive symptoms along with neuropsychiatric or neu-
rological symptoms. All of the definitions also underscore the possible
autoimmune etiology of these disorders, and the difference between
these cases and cases of non-autoimmune OCD. However, the diag-
nostic criteria are based not on signs of autoimmunity, but on clinical
presentation and psychiatric symptoms.
Diagnosis of PANDAS and related disorders is challenging, owing to
the wide variation in the presentation of symptoms and course. The
symptomatology of these disorders may overlap with almost any other
psychiatric condition, thereby complicating differential diagnosis. The
patient’s family may observe a brief period of subtle obsessive-com-
pulsive symptoms that emerges gradually and regresses spontaneously.
Families often note that these behaviors would have been forgotten if
not for the sudden and dramatic subsequent onset of symptoms.
1.2. Treatments
Cognitive behavior therapy (CBT) including exposure and response
prevention (ERP), and selective serotonin reuptake inhibitors (SSRIs)
are the primary evidence-based therapies for OCD (Team POTSP,
2004). Approximately 50%–80% of patients with OCD respond to these
treatments (Grant, 2014), but a substantial proportion of patients sub-
sequently experience lifelong treatment resistance (Grant, 2014). Be-
havioral interventions, such as habit reversal training, and psycho-
pharmacological treatment strategies are the recommended treatments
for tic disorders (Hollis et al., 2016). In contrast to the recommended
treatments, when an infectious or autoimmune etiology is suspected,
these treatments for OCD and tics may be insufficient.
Supplemental or alternative treatment options when suspecting
PANDAS include antibiotics or tonsillectomy to treat and/or prevent
GABHS infection (Pavone et al., 2014). To suppress the immune system
in patients with putative autoimmune-based OCD corticosteroids
(Frankovich et al., 2015), therapeutic plasma exchange (TPE) (Latimer
et al., 2015;Perlmutter et al., 1999), intravenous immunoglobulin
(IVIG) (Perlmutter et al., 1999), or anti-CD20 monoclonal antibodies
(rituximab) (Frankovich et al., 2015) have been given. Administration
of nonsteroidal anti-inflammatory drugs (NSAIDs) to ameliorate psy-
chiatric symptoms of PANDAS and PANS also has been suggested and is
in line with the autoimmune etiology theory (Chiarello et al., 2017).
Recently, a consortium of clinicians and researchers have authored
three consensus papers regarding treatment of PANDAS and PANS
using psychiatric and behavioral interventions (Thienemann et al.,
2017), immunomodulatory therapies (Frankovich et al., 2017) and
antibiotics (Cooperstock et al., 2017). These guidelines of the clinical
management of PANDAS and PANS are based on clinical experience
and on research, and support use of immunomodulatory treatment and
antibiotics, beside standard psychiatric treatment.
2. Objective
Our objectives were to evaluate studies in which patients with
PANDAS, PANS, CANS, or PITAND were given treatment and to de-
termine whether there was sufficient evidence to recommend adoption
of specific therapies for these patients.
3. Methods
3.1. Information sources and search strategy
This study was designed as a systematic review of research studies
and case reports in which patients with PANDAS, PANS, PITAND, or
CANS received treatment. The study was carried out in accordance with
PRISMA guidelines (Moher et al., 2009). PubMed, Cochrane Library,
and Scopus databases were searched from the earliest start date avail-
able for the databases to February 15, 2017 (Scopus), February 20,
2017 (Cochrane Library), or February 20, 2017 (PubMed). Additional
searches of PubMed, Scopus, and Cochrane Library were conducted on
May 31, 2017 and October 27, 2017. No MeSH (i.e., medical subject
headings) terms were found for PANDAS, PANS, PITAND or CANS.
Therefore, the following free text search words were used: (1) “pedia-
tric autoimmune neuropsychiatric disorders associated with strep*.”(2)
“pediatric acute-onset neuropsychiatric syndrome.”(3) “childhood
acute neuropsychiatric symptoms.”and (4) “pediatric infection-trig-
gered autoimmune neuropsychiatric disorders.”In Scopus, the docu-
ment type was set to “article.”No filters were applied in searches of
Cochrane Library or PubMed.
Table 1
Diagnostic criteria for PANDAS, PANS and CANS.
PANDAS (Swedo et al., 1998) PANS (Swedo et al., 2012) CANS (Singer et al., 2012) PITAND (Allen et al., 1995)
OCD and/or tic syndrome (DSM-IV)
Prepubertal symptom onset Episodic
course, abrupt onset of symptoms or of
symptom exacerbation Association with
GABHS infection (positive throat culture
and/or elevated anti-GABHS antibody
titers) Association with neurological
abnormalities
Abrupt, dramatic onset of OCD or
severely restricted food intake
Additional neuropsychiatric
symptoms, ≥2 of the following:
Acute dramatic onset of symptoms Primary
criterion: OCD Secondary criterion: tics,
dysgraphia, hyperactivity, clumsiness,
anxiety, psychosis, emotional lability,
developmental regression, sensitivity to
sensory stimuli Mono/polyphasic course
Pediatric onset Lifetime OCD or tic disorder
Sudden onset, or a pattern of sudden,
recurrent, clinically significant symptom
exacerbations and remissions
Exacerbations not exclusively related to
stress or illness. Un treated exacerbations
last at least 4 weeks. Exacerbations severe
enough to suggest treatment modification.
During OCD and/or tic exacerbations, the
majority of patients will have an abnormal
neurological examination, frequently with
adventitious movements Evidence of an
antecedent or concomitant infection.
Patients may or may not continue to have
clinically significant symptoms between
episodes of OCD and/or tic disorder.
- Anxiety
- Emotional lability and/or
depression
- Irritability, aggression and/or
severely oppositional behavior
- Behavioral regression
- Deterioration in school
performance
- Sensory or motor abnormalities
- Somatic symptoms, including
sleep disturbances, enuresis or
urinary frequency
- Symptoms not better explained
by neurological or medical
disorder
PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.
PANS: Pediatric acute-onset neuropsychiatric syndrome.
CANS: Childhood acute neuropsychiatric symptoms.
PITAND: Pediatric Infection-triggered autoimmune neuropsychiatric disorders.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
52
3.2. Eligibility criteria and study selection
Article abstracts were screened by either of the investigators (E.H.
or S.S.) for relevant content, and articles with empirical data regarding
treatments were accessed for further review. Articles were included that
(1) applied diagnostic criteria for PANDAS, PANS, CANS, or PITAND;
(2) presented treatment and outcome data; and (3) were written in
English. Articles then were categorized as a study or a case report. A
study was defined as an analytic article of defined treatments with
prospectively defined outcome measures. A case report was defined as a
retrospective presentation of treatment outcomes presented in a de-
scriptive article. Case report articles could contain data from single or
multiple cases.
3.2.1. Quality assessment of treatment-related studies
All articles defined as studies were assessed for possible bias using
standardized forms prepared by the Swedish Agency for Health
Technology Assessment and Assessment of Social Services (SBU,
2014aa,b). Types of bias assessed included selection bias, performance
bias, detection bias, attrition, reporting bias and other bias. Following
evaluation, each study was categorized as having an overall low,
moderate, or high risk of bias. The overall risk was determined to be the
highest score given at least twice in the scoring tool.
3.2.2. Data extraction
The full texts of all included studies were read, and the following
data were extracted: study design, number of participants, diagnosis,
treatment given, control condition, main outcome measure, time to
follow-up, and main results. Full texts of included case reports also were
read, and the following data were extracted: number of cases, gender,
age, diagnosis, presence of tics and OCD, OCD subtype, presence of
aggression, treatments, treatment outcome, follow-up time, and follow-
up outcome. Treatment outcomes were rated on a 4-point scale, in
which 1 indicated no improvement, and 4 indicated that the authors
stated in the text that symptoms were in “full remission.”or “com-
pletely resolved.”Two investigators (E.H. and S.S.) independently read
and extracted data from all articles.
4. Results
4.1. Available literature
The literature searches returned 234 articles from PubMed, 15 ar-
ticles from Cochrane Library, and 837 articles from Scopus. After re-
moving duplicates, 973 articles were compiled for abstract screening. A
total of 811 articles failed to meet inclusion criteria, and 162 articles
were included for full-text review. Seventy-seven of the 162 articles met
inclusion criteria after full-text review. Of these, 11 were treatment
studies, one was a survey study and 65 were case series or case reports.
Our systematic approach for selection of articles is summarized in
Fig. 1.
4.1.1. Treatment studies
Of the 11 treatment studies, 4 were double-blind randomized con-
trolled studies (RCTs) (Murphy et al., 2017;Perlmutter et al., 1999;
Snider et al., 2005;Williams et al., 2016), one was a cross-over trial
(Garvey et al., 1999), 2 were open trials (Nadeau et al., 2015;Storch
et al., 2006) and 4 were observational studies (Brown et al., 2017a,b;
Murphy et al., 2013;Pavone et al., 2014). The 11 studies included a
total of 529 patients; the 4 RCTs included a total of 90 patients. At least
two studies were based on the same study population (Brown et al.,
2017a,b). Treatments evaluated in the 11 studies were penicillin, azi-
thromycin, IVIG, TPE, tonsillectomy, CBT, corticosteroids and NSAID.
In addition to the 11 treatment studies, one large survey study was also
included. The survey study was based on parent reports of 698 cases
with PANS, reporting treatment frequency and effect of antibiotics,
anti-inflammatory medications, IVIG, TPE, psychotropic medications,
psychotherapy and complementary and alternative medicines
(Calaprice et al., 2017). All studies are listed in Table 2.
4.1.1.1. Quality assessment of the treatment studies. Eleven of the 12
studies had a high or moderate risk of bias. Three treatment studies had
no control group. Randomization was inadequately described in 2 of
the 4 RCTs. Only 1 study—in which IVIG was evaluated (Williams et al.,
2016)—had a low overall risk of bias. The eleven treatment studies had
small sample sizes, ranging from 7 to 37 participants in the RCTs, cross
over study and open trials; and 43 to 120 participants in the 4
observational studies. The survey study had a larger sample
(n = 698), but these participants were self-selected and the outcomes
self-reported, resulting in a high risk of bias (Calaprice et al., 2017). In
Table 3, results of our bias assessment are presented.
4.1.2. Case reports
The 65 case reports involved a total of 240 patients. In 6 of the
articles, the authors presented data in summarized form as case series.
Treatments noted in the case reports included antibiotics and tonsil-
lectomy to address the infectious agent; IVIG, TPE, corticosteroids,
NSAID and anti-CD20 monoclonal antibodies for immunomodulation;
and psychotropic medications and CBT for psychiatric symptoms. In the
6 case series, the authors evaluated the response to antibiotics (Murphy
and Pichichero, 2002), antibiotics in combination with tonsillectomy
(Demesh et al., 2015), TPE alone or in combination with antibiotics
(Beşiroǧlu et al., 2007;Latimer et al., 2015), treatment of sinusitis
(Mahony et al., 2017) and NSAID (Spartz et al., 2017). Our systematic
review of case reports is presented in Supplementary Table S1.
4.2. Treatments for PANS, PANDAS, PITAND, and CANS
4.2.1. Antibiotics
Various antibiotics have been used to treat patients with PANDAS
and related conditions. These include penicillin, macrolides (e.g., azi-
thromycin), and cephalosporins (e.g., cefdinir). In 2 studies, the pro-
phylactic effect of antibiotics on PANDAS was determined (Snider et al.,
2005;Garvey et al., 1999). In another study, the effect of antibiotics on
PANS was assessed (Murphy et al., 2017). Garvey et al. (1999) found
that penicillin prophylaxis was not superior to placebo to prevent
streptococcal infection and thereby avoid exacerbation of psychiatric
symptoms, nor did it lead to fewer symptom exacerbations. Because this
was a prophylaxis study aimed at preventing exacerbations rather than
treating existing symptoms the results of this study should not be in-
terpreted as a failure of penicillin to treat current PANDAS symptoms.
Snider et al. (2005) evaluated frequency of streptococcal infections and
psychiatric exacerbations as outcome measures in a trial of penicillin
versus azithromycin; a placebo arm was not included in this study. The
authors demonstrated that the treatments were equally effective in
preventing exacerbations, but the absence of a placebo arm limited the
conclusions that could be drawn from the study.
Murphy et al. (2017) conducted a study in which children with
PANS and current psychiatric symptoms were treated with azi-
thromycin or placebo. These authors found no significant treatment
effect of azithromycin based on the CY-BOCS, but this treatment pro-
duced a modest effect as assessed by CGI-S (Guy and ECDEU, 1976), a
seven point global measure of functioning which may be more sensitive
to change than CY-BOCS. In the study by Snider et al. (2005), 500 mg of
azithromycin was given per week as prophylaxis for PANDAS; in the
study by Murphy et al. (2017), the dose was much higher (10 mg/kg up
to 500 mg per day; i.e., 3500 mg per week).
In the large survey study, 97% of 698 patients reported that they
had been treated with antibiotics for PANS-associated infections
(Calaprice et al., 2017). The most commonly received antibiotics were
amoxicillin, azithromycin and amoxicillin-clavulanate. Out of 235 pa-
tients receiving amoxicillin, 20% reported treatment to be “very
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
53
effective”whereas 28% chose to discontinue treatment due to lack of
efficacy. Corresponding proportions for azithromycin (n = 216) were
26% reported as “very effective”and 23% discontinuation due to lack
of efficacy. 30% of patients treated with amoxicillin-clavulanate
(n = 184) reported the treatment to be “very effective”, and 22% chose
to discontinue due to lack of efficacy.
In contrast to the modest effects described in the 3 treatment studies
(Brown et al., 2017a,b;Murphy et al., 2013), results of several case
reports indicate that antibiotics have a positive effect on psychiatric
symptoms of PANDAS and related disorders. We have identified case
reports comprising a total of 130 patients treated with antibiotics.
Twenty-seven patients were treated only with antibiotics, and 5 of these
patients indicated complete remission of symptoms after treatment. In
general, the case reports varied in terms of type of antibiotics given and
dosage. Supplementary Table S2 summarizes data from the case reports
involving antibiotics as treatment.
To summarize, antibiotics have been described in 130 case reports.
Moreover, antibiotics have been reported to be effective in 8–52% of
treated cases in a large survey study, depending on dose and type.
Antibiotics have been tested in two RCTs and one cross-over study with
mixed results and outcome measures. Therefore, the evidence for using
antibiotics for PANS, PANDAS, PITAND and CANS is inconclusive.
4.2.2. Therapeutic plasma exchange
One study of TPE for treatment of PANDAS was identified in the
literature review. In this study, the authors examined the effect of TPE
in 10 children with PANDAS in an open-label placebo-controlled setting
(Perlmutter et al., 1999). (A third arm in this study was double-blind
treatment with IVIG, described herein in Section 4.2.3 Intravenous
immunoglobulin.) The 3 treatments (TPE, IVIG, and placebo-IVIG) were
compared at the 1-month follow-up visit. The authors found a striking
improvement in the TPE group compared to placebo, and symptoms
remained improved from baseline on all measures at the 1-year open
follow-up assessment.
In the survey study only 25 out of 698 patients received TPE. 15 of
these reported a positive response but only 6 patients experienced an
enduring positive effect (Calaprice et al., 2017).
In addition to the above studies a total of 7 case reports and case
series comprising 45 patients treated with TPE were identified in the
literature review.
Latimer et al. (2015) conducted a retrospective case series of all 40
patients treated with TPE on psychiatric indication at Georgetown
University Hospital; 5 of these patients were lost to follow-up. Of the
remaining 35 patients, an average duration of 4.2 years of illness was
observed, and all had been treated with antibiotics without improve-
ment. Five patients were non-responders to oral corticosteroids and 17
to IVIG. After TPE, a 78% reduction in symptom severity was reported
during follow-up (6 months to 5.4 years post-treatment). Notably, im-
provement was not associated with duration of illness (Latimer et al.
2015).
Another case series included 4 adults with both tics and OCD
(Beşiroǧlu et al., 2007). Symptoms were assessed prospectively and in a
systematic manner. All patients had been treated previously with SSRIs
and neuroleptics without favorable results. Following TPE, these pa-
tients experienced remarkably positive effects, with a mean reduction
in Y-BOCS score of 20 points. All patients also had improvement in tics.
In 1 case report, a patient with PANDAS had symptoms “fully re-
solved”with TPE treatment (Elia et al., 2005). One case was treated
with combination of TPE and rituximab, following treatment with both
corticosteroids with mycophenolate mofetil and IVIG, resulting in
symptom remission (Frankovich et al., 2015). Results described in 2
other case reports were modest (Giedd et al., 1996;Sadhasivam and
Fig. 1. Flowchart of literature search and inclusion
of articles. The flowchart follows the PRISMA
guidelines.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
54
Table 2
Study design, study population, follow-up, intervention and outcome measures of included studies.
First author Study design,
follow-up (m),
treatment type
Study population (age) Intervention
S = subject,
C = control
Outcome measures Results
Garvey
et al.
(1999)
Balanced cross-
over study,
double-blinded
(8) antibiotics
37 children meeting criteria for PANDAS (9.61 ± 2.59 yrs.) S: PcV (250 mg) twice
daily during 4 months
C: Placebo (250 mg)
twice daily during 4
months
Symptom severity
using YGTSS, CY-
BOCS and NIMHRS,
Number of
streptococcal
infections
PcV = Placebo
Snider et al.
(2005)
RCT, double-
blinded (12),
antibiotics
23 children meeting criteria for PANDAS (7.9 ± 1.3 yrs.) S: Azithromycin
(250 mg) twice daily 1
d/week, placebo
capsule 6 d/week
(n = 12) during 12
months C: S: PcV
(250 mg) twice daily 1
d/week, placebo
capsule 6 d/week
(n = 11) during 12
months
Primary: number of
GAS infections
Secondary: number
of neuropsychiatric
exacerbations
Azithromycin = PcV
Murphy
et al.
(2017)
RCT, double-
blinded (1),
antibiotics
31 children meeting criteria for PANS (mean 8.26 yrs.) S: Azithromycin
(10mg/kg up to 500mg
per day) and probiotic
for 4 weeks (n = 17) C:
Placebo and probiotic
for 4 weeks (n = 14)
Primary: Severity of
OCD using CGI-S
OCD and CY-BOCS
Secondary: CGI-I, C-
GAS, YGTSS, SNAP-
IV, CALS, SCARED
Azithromycin > Placebo.
However, effects were small
and there was no reduction
in CY-BOCS, only in OCD-
CGI-S
Perlmutter
et al.
(1999)
RCT, double-
blinded to IVIG-
and placebo
group, not
blinded to TPE
group (12), IVIG
and TPE
29 children meeting criteria for PANDAS (TPE 10.3 ± 2.8 yrs.; IVIG 9.1 ± 2.4 yrs.; placebo 9.4 ± 08 yrs.) S: IVIG (1g/kg/d for 2
d) (n = 9) S: TPE (1
plasma volume/
procedure, 5 or 6
procedures) (n = 10)
C: saline solution (1g/
kg/d for 2 d) (n = 10)
Placebo non-
responders offered
IVIG
Severity of
neuropsychiatric
symptoms using
TSURS, CY-BOCS,
CGI-S, GAS, and
NIMHRS
TPE > IVIG > Placebo
Williams
et al.
(2016)
RCT, double-
blinded (6), IVIG
35 children meeting criteria for PANDAS (IVIG 8.99 ± 2.37; placebo 9.61 ± 2.32 yrs.) S: IVIG (1 gm/kg/d on
2 consecutive days,
total dose 2 gm/kg)
(n = 17) C: IV placebo
(n = 18) Non-
responders to blinded
infusion were offered
open-label IVIG at
week 6 (n = 24)
Primary: CY-BOCS
and CGI-I
IVIG = Placebo
Murphy
et al.
(2013)
Observational
study,
prospectively
assessed (> 12),
tonsillectomy
43 children meeting criteria for PANDAS, 69 children with OCD and/or tics not meeting PANDAS criteria (9.2 ± 2.4 yrs.) S: Previous
tonsillectomy and/or
adenoidectomy
(n = 32) C: No surgery
(n = 76)
Symptom severity
using CY-BOCS and
YGTSS
Tonsillectomies and
Adenoidectomies = No
surgery
Pavone
et al.
(2014)
Observational
study,
prospectively
assessed (> 24),
tonsillectomy
120 children meeting criteria for PANDAS (11.05 + 1.2 yrs.) S: Previous
tonsillectomy (n = 25)
or adenotonsillectomy
(n = 31) C: No surgery
(n = 64)
Symptom severity
using CY-BOCS and
YGTSS
Tonsillectomies and
Adenoidectomies = No
surgery
(continued on next page)
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
55
Table 2 (continued)
First author Study design,
follow-up (m),
treatment type
Study population (age) Intervention
S = subject,
C = control
Outcome measures Results
Storch et al.
(2006)
Waitlist
controlled open
trial, blind to
rater (3), CBT
7 children meeting criteria for PANDAS (11.1 ± 1.4 yrs.) S: 14 CBT sessions over
3 weeks (up to 4
booster sessions)
(n = 7) C: Waitlist
Primary: CY-BOCS,
CGI-S, ADIS-IV-P,
CGI-I and remission
status Secondary:
TODS-PR, CDI and
MASC-10
CBT ameliorated OCD
symptoms, but not
depression or anxiety. No
comparison group
Nadeau
et al.
(2015)
Open trial,
intervention
study, not
controlled (1-4),
CBT
11 children meeting PANDAS or PANS criteria (9.4 ± 2.7 yrs.) S: Maximum of 14 CBT
session in person or via
webcam on a twice-
weekly schedule
(n = 11)
Primary: CY-BOCS,
CGI-S and CGI-I
Secondary: SCARED
and COIS-C/P
Treatment ameliorated OCD
symptoms (CY-BOCS) and
general function (CGI-S). No
comparison condition.
Brown et al.
(2017a-
,b)
Observational
study,
retrospectively
assessed, NSAID
95 patients meeting criteria for PANS and/or PANDAS with 390 flares in total S: Prophylactic
(n = 76) or early
(n = 43) NSAID
treatment C: No NSAID
treatment (n = 271)
Primary: PANS flare
duration Secondary:
Impact of timing of
NSAID introduction
on PANS flare
duration
NSAID > Control
Brown et al.
(2017a-
,b)
Observational
study,
retrospectively
assessed,
corticosteroids
98 patients meeting criteria for PANS and/or PANDAS with 403 flares in total S: Oral corticosteroid
burst treatment
(n = 85) C: No
corticosteroid burst
treatment (n = 318)
Primary: PANS flare
duration Secondary:
Impact of timing of
corticosteroid
introduction on
flare duration and
effect of course
length on duration
of symptom
improvement
Corticosteroids > Control
Calaprice
et al.
(2017)
Observational
study,
retrospectively
assessed, self-
reported, mixed
treatments
698 patients with self-reported PANS S: various treatments
for PANS
Primary: Frequency
of treatment
Secondary: Self-
reported effect of
treatment
N/A
PANDAS = Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections; PANS = Pediatric acute-onset neuropsychiatric syndrome; RCT = Randomized controlled trial; IVIG= Intravenous Immunoglobulin;
TPE = Therapeutic plasma exchange; OCD=Obsessive-compulsive disorder; YGTSS = Yale Global Tic Severity Scale; TSURS = Tourette Syndrome Unified Rating Scale; CY-BOCS= Children’s Yale-Brown Obsessive-Compulsive Scale; CGI-
S = Clinical Global Impression Severity scale; CGI-I = Clinical Global Impression Improvement scale; ADIS-IV-P = Anxiety Disorders Interview Schedule Parent version; GAS = Global Assessment Scale; C-GAS = Child-Global Assessment Scale;
TODS-PR = Tourette’s Disorder Scale-Parent Rated version; CDI = Children’s Depression Inventory; COIS-C/P = Child Obsessive Compulsive Impact Scale-Child/Parent versions; CBCL = Child Behavior Checklist; MASC-10 = Multidimensional
Anxiety Scale for Children-10; SCARED = Screen for Childhood Anxiety Related Emotional Disorders; NIMHRS= National Institute of Mental Health Rating Scales for global functioning, anxiety and depression; CALS =Children’sAffective Lability
Scale; NSAID = Nonsteroidal Anti-Inflammatory Drugs.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
56
Table 3
Results and quality assessment of included studies.
First author
(intervention)
Results Risk of bias Support for judgement
Select-ion
B1
Perform-ance
B2
Detect-ion
B3
Attrit-ion
B4
Report-ing
B5
OtherB6 Over-all
Garvey et al. (1999)
(PcV)
NIMH depression and anxiety
scales showed significant
improvement during active
phase, no significant
difference between the two
phases regarding OCD and tic
severity or exacerbations was
seen. Fewer streptococcal
infections during the active
phase (n = 14) than in the
placebo phase (n = 21) but
the difference was not
statistically significant.
22 112 22B1: randomization
procedure not reported. B2:
lack in compliance,
difference in off-study
antibiotics. B3: validated
scales, acceptable follow-
up. B4: low drop-out rate.
B5: primary/ secondary
outcome and AE not
reported. B6: information
missing.
Snider et al. (2005)
(Azithromycin/
PcV)
Number of neuropsychiatric
exacerbations decreased in
PcV group, 23 to 6, and in
azithromycin group, 21 to 11,
(p < 0.01), non-significant
between groups.
Streptococcal infections
decreased in both groups
(p < 0.01), but no
significant difference
between groups.
31 212 12B1: randomization and
baseline differences not
stated.B2: double-blind
study, good compliance.
B3: all scales not validated.
B4: low drop-out rate. B5:
AE not reported.B6:
funding reported
Murphy et al. (2017)
(Azithromycin)
No significant difference in
CY-BOCS scores between
groups was seen. There was a
significant reduction in CGI-S
OCD in the azithromycin
group compared to placebo;
21.76 % and 0.95 % in
average respectively. Tic
severity moderated treatment
response in the azithromycin
group.
11 223 12B1: randomization by
pharmacy. B2: double-
blind design B3: validated
scales, unclear statistics.
B4: 1 randomized person
not in analysis. B5: pre-
published protocol deviate
from outcomes reported.
B6:financial disclosures
complete
Perlmutter et al.
(1999) (IVIG/
TPE)
1-month follow-up: IVIG and
TPE showed significant
improvement of all
neuropsychiatric scores
except GAS and tic severity
compared to placebo, TPE
also showed significant
improvement in tic severity
compared to placebo. 1-year
follow-up: Symptoms
remained improved from
baseline for both IVIG and
TPE.
22 112 22B1: randomization
procedure not reported,
difference in tic severity
between groups. B2: TPE
group not blinded,
difference in off-study
medication. B3: validated
scales, short and long term
follow-up. B4: low drop-out
rate. B5: primary/
secondary outcome not
reported. B6: information
missing
(continued on next page)
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
57
Table 3 (continued)
First author
(intervention)
Results Risk of bias Support for judgement
Select-ion
B1
Perform-ance
B2
Detect-ion
B3
Attrit-ion
B4
Report-ing
B5
OtherB6 Over-all
Williams et al. (2016)
(IVIG)
Week 6: Mean decrease in CY-
BOCS was 24% in the IVIG
group and 12% in the placebo
group, difference not
statistically significant. CGI-I
scores did not differ
significantly between the
groups either. CY-BOCS total
scores at end of follow-up
(week 24) were improved by
62%.
11 111 11B1: randomization method
reported, equal groups.B2:
double-blind study, good
compliance.B3: validated
scales, acceptable follow-
up.B4: low drop-out rate,
reason reported.B5:
primary outcome stated,
published study protocol.
B6:financial disclosures
complete
Murphy et al. (2013)
(Tonsillectomy)
Most participants had surgery
before onset of symptoms and
surgery did not affect
symptomology, no difference
in CY-BOCS or YGTSS scores
was seen between the groups
11 212 22B1: similar group
configuration.B2:
observational study, good
compliance.B3: evaluator
not blinded.B4: low drop-
out rate B5: AE not
reported.B6: information
missing
Pavone et al. (2014)
(Tonsillectomy)
Surgery did not increase
number of patients with
resolution of symptoms
(RR = 1.39; p = 0.29). No
difference in CY-BOCS or
YGTSS scores was seen
between the groups.
22 222 22B1: baseline characteristics
not reported.B2:
observational study,
difference in off-study
treatment.B3: raters not
unbiased B4: drop-out not
reported.B5: AE not
reported.B6: information
missing
Storch et al. (2006)
(CBT)
Clinician severity ratings (CY-
BOCS, ADIS-P) decreased
significantly after CBT-
intervention, maintained at
follow-up, 71% and 50% was
considered not having an
OCD diagnosis on the ADIS-P
post treatment and follow-up,
respectively. Self-reported
anxiety and depression was
not significantly reduced.
33 111 13B1: not randomized,
waitlist controlled. B2: not
blinded, up to 4 booster-
sessions. B3: validated
scales, acceptable follow-
up B4: low drop-out rate,
reason reported. B5:
primary/secondary
outcome measures
reported. B6:financial
disclosures complete
Nadeau et al. (2015)
(CBT)
Significantly lower CY-BOCS
score post treatment (13.2)
compared to pretreatment
(25.8). Significant decrease in
CGI-S score pre- to post
treatment (3.8 to 2.1).
Significant difference in
COIS-P, no significant
difference in COIS-C or
SCARED.
33 231 13B1: no randomization, not
controlled. B2: not
blinded.B3: follow-up
ranging from 1–4 months.
B4: high drop-out rate. B5:
primary/secondary
outcome measures
reported.B6:financial
disclosures complete
(continued on next page)
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
58
Table 3 (continued)
First author
(intervention)
Results Risk of bias Support for judgement
Select-ion
B1
Perform-ance
B2
Detect-ion
B3
Attrit-ion
B4
Report-ing
B5
OtherB6 Over-all
Brown et al.
(2017a,b)
(NSAID)
Prophylactically treated
flares were about 4 weeks
shorter, and early treated
flares about 2.5 weeks shorter
than flares not treated with
NSAID (12.2 weeks long). In
early treated flares, each day
that NSAID treatment was
delayed was associated with
an increase in flare duration
of 0.18 weeks; this
relationship however was
nonsignificant when adding
all covariates (p= 0.06).
22 211 12B1: difference in baseline
characteristics. B2:
difference in off-study
medication. B3: evaluator
not blinded, unvalidated
scales. B4: low drop-out
rate. B5: AE reported,
relevant outcome
measures. B6:financial
disclosure complete
Brown et al. (2017a,
b)
(Corticosteroid)
Flares treated with
corticosteroids were
significantly shorter
(6.4 ± 5.0 weeks) than
flares not treated with
corticosteroids (11.4 ± 8.6
weeks). Treatment initiated
early in flare was associated
with shorter flare duration,
and longer corticosteroid
course generated longer
duration of symptom
improvement.
22 211 12B1:difference in baseline
characteristics. B2:
difference in off-study
medication. B3: evaluator
not blinded, unvalidated
scales. B4: low drop-out
rate. B5: AE reported,
relevant outcome
measures. B6:financial
disclosure complete.
Calaprice et al.
(2017) (various
treatments)
97% had any type of
antibiotics, 63% had any type
of anti-inflammatory
treatment and 54% reported
any type of psychotropic
treatment. Broad-spectrum
antibiotics and courses > 30
days produced best results
among antibiotics. 31% had
received IVIG, and of these
49% reported it to be “very
effective”.
33 331 13B1: self-selected sample.
B2: observational study,
multiple treatments given.
B3: self-reported outcomes,
survey study. B4: non-
responders not reported.
B5: adequate study
protocol and outcome
measures. B6: financial
disclosure complete.
Risk of bias: 1 = low risk, 2 = moderate risk, 3 = high risk; OCD=Obsessive-compulsive disorder; IVIG = Intravenous immunoglobulin; TPE = Therapeutic plasma exchange; PcV = Penicillin V; CBT = Cognitive behavior therapy; GAS = Global
Assessment Scale; CY-BOCS=Children’s Yale-Brown Obsessive-Compulsive Scale; YGTSS = Yale Global Tic Severity Scale; CGI-S/I = Clinical Global Impression-Severity/Improvement scale; COIS-C/P = Child Obsessive Compulsive Impact Scale-
Child/Parent version; SCARED = Screen for Childhood Anxiety Related Emotional Disorders; ADIS-P=Anxiety Disorders Interview Schedule Parent version; AE = adverse events; NSAID = Nonsteroidal Anti-Inflammatory Drugs.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
59
Litman, 2006). Two patients with PITAND who underwent TPE also had
improvement in symptoms (Allen et al., 1995).
TPE has been described in multiple case reports and case series. In
the survey study, only 6 out of 25 treated patients reported enduring
improvement following TPE. In contrast, the two systematically per-
formed case series reported positive outcomes. Furthermore, TPE has
been tested in a controlled setting but the available literature has sev-
eral limitations, most notably that no study involved blinding.
Therefore, the evidence for TPE is inconclusive.
4.2.3. Intravenous immunoglobulin
Contradictory results of IVIG treatment were found in 2 double-
blinded RCTs (Perlmutter et al., 1999;Williams et al., 2016). In the
study by Perlmutter et al. (1999), 9 children with PANDAS treated with
IVIG improved considerably compared to a placebo group at 1 month of
follow-up. However, these patients were assigned to open-label IVIG
after 1 month, which precluded any long-term placebo comparison.
Williams et al. (2016) applied a similar study design but did not de-
monstrate an effect of IVIG versus placebo during the double-blind
phase. In the subsequent open-label phase, the majority of patients
improved on IVIG. These authors did not determine a factor that pre-
dicted favorable treatment response, but elevated baseline levels of
serum calcium calmodulin-dependent protein kinase II (CaMKII) and
anti-nuclear antibody (ANA) were associated with treatment response
in a post hoc analysis (Williams et al., 2016).
In the survey study treatment with IVIG was reported for 206 pa-
tients; however, therapeutic impact was only reported for 191 patients
(Calaprice et al., 2017). IVIG was reported “very effective”for 49% of
the treated patients, “somewhat effective”for 25% and “not very ef-
fective”for 11%.
An additional 6 case report papers (Allen et al., 1995;Frankovich
et al., 2015;Gerardi et al., 2015;Hachiya et al., 2013;Kovacevic et al.,
2015;Murphy et al., 2014) involving a total of 19 patients addressed
treatment of patients with PANDAS, PITAND, or PANS using IVIG. Ten
of these patients were presented in a case series of a combination
treatment of IVIG and corticosteroids (Kovacevic et al., 2015). Eleven of
the 19 patients experienced full remission of symptoms following IVIG
(Frankovich et al., 2015;Kovacevic et al., 2015;Murphy et al., 2014).
IVIG has been described in multiple case reports and case series.
Results from the self-reported survey study provides some support for
IVIG being perceived as an effective treatment for PANS. IVIG has been
tested in two double-blind RCTs, with the higher quality study in-
dicating low support. Therefore, the evidence for using IVIG is incon-
clusive.
4.2.4. Tonsillectomy and adenoidectomy
Outcomes of tonsillectomy and/or adenoidectomy were reported in
2 prospective observational studies (Murphy et al., 2013;Pavone et al.,
2014). Authors of these studies came to the same conclusion: symptom
severity was not dependent of having a tonsillectomy or adenoi-
dectomy. However, Murphy et al. (2013) observed a significantly
higher number of previously conducted tonsillectomies in the PANDAS
group compared with children unaffected by PANDAS, OCD or tics. This
finding could be due to a confounding by indication, e.g. that previous
strep infections could increase the risk both for PANDAS and for a
tonsillectomy.
Another 24 patients who underwent tonsillectomy and/or adenoi-
dectomy were identified in the reviewed literature (Alexander et al.,
2011;Batuecas Caletrío et al., 2008;Boseley et al., 2007;Calkin and
Carandang, 2007;Chmelik et al., 2004;Demesh et al., 2015;Frankovich
et al., 2015;Fusco et al., 2010;Heubi and Shott, 2003;Lynch et al.,
2006;Orvidas and Slattery, 2001). In 1 case series, 9 patients with
PANDAS were treated with antibiotics and tonsillectomy and all im-
proved (Demesh et al., 2015).
Tonsillectomy and/or adenoidectomy has been described in mul-
tiple case report and case series. It has not been tested in a controlled
setting, but two observational studies indicate no support. In line with
this, the evidence for treating PANDAS with tonsillectomy and/or
adenoidectomy is weak.
4.2.5. Cognitive behavior therapy
In 2 studies (Nadeau et al., 2015;Storch et al., 2006), authors
evaluated the effect of CBT on symptoms of OCD in patients with
PANDAS and PANS. Results of both studies showed a significant de-
crease in OCD symptom severity. However, these studies were pre-
liminary and limited by lack of an active control group and small
sample sizes (7 and 8 participants, respectively). Furthermore, Nadeau
et al. (2015) had an over 40% drop-out rate, leaving only 6 patients
evaluated at follow-ups ranging from 1 to 4 months. The use of anti-
biotics also may have influenced the outcome of this study (Nadeau
et al., 2015).
The survey study reported 473 out of 698 patients receiving some
form of psychotherapy (Calaprice et al., 2017). Patients who had re-
ceived the recommended treatment for OCD (exposure with response
prevention, ERP) reported the treatment to be “very effective”in 39%
of treated cases.
CBT techniques, including psychoeducation and ERP, were applied
in 7 case reports of patients with PANDAS (Calkin and Carandang,
2007;Frankovich et al., 2015;Gabbay and Coffey, 2003;Giedd et al.,
1996;Kuluva et al., 2008;Lawrence and Baggott, 2017;Sharma et al.,
2012) and 2 case reports of patients with PANS (Frankovich et al.,
2015;Muir et al., 2013). No case report involved CBT as the main
treatment of PANS or PANDAS symptoms. Although CBT is an evidence-
based treatment for OCD, few authors have examined patients with
OCD of potential autoimmune etiology.
CBT as treatment for PANS or PANDAS has been described in sev-
eral case reports. The survey study lends some support for treating
PANS-related OCD with ERP. Two uncontrolled studies indicated that
CBT ameliorated OCD symptoms in patients with PANS or PANDAS.
Hence, it is possible that patients who fulfill PANS or PANDAS criteria
could benefit from CBT treatment, but this has not been tested in a
controlled setting. Therefore, the evidence for CBT is inconclusive.
4.2.6. Nonsteroidal anti-inflammatory drugs
One observational study of NSAID as treatment for PANS was
identified in the review (Brown et al., 2017b). This study was a retro-
spective assessment on the duration of flares in PANS patients following
treatment with or without NSAID. Of the first 218 consecutive patients
at a PANS clinic, 95 patients treated with NSAID were evaluated. A total
of 390 flares experienced by the patients were evaluated. Flares not
treated with NSAID had a mean duration of 12.2 weeks. Flares treated
with NSAID were shortened by 4 weeks (95% CI 1.85–6.24 weeks)
when patients were on prophylactic NSAID, and 2.6 weeks (95% CI
0.43–4.68 weeks) when flares were treated within 30 days of flare
onset. This study excluded 17 patients who required treatments with
rituximab, cyclophosphamide, mycofenolate mofetil or chronic im-
munomodulatory therapy. Whether or not these patients were treated
with NSAID, and how they responded, is unclear. It is also unclear in
the study if all untreated flares at the clinic were included. Transient
side effects were experienced by 19% of the patients.
One large case series has evaluated the use of NSAID in PANS
(Spartz et al., 2017). This study was based on the same sample of the
first 218 consecutivepatients treated at the Stanford PANS clinic as
Brown et al., (2017b). Seventy-seven patients experiencing a total of
109 occurrences of change in treatment regime consisting of only ad-
dition (n = 52) or removal (n = 57) of NSAID were described. The
patients were regarded as responders to NSAID treatment if they im-
proved after addition of NSAID or deteriorated after removal of NSAID.
In total, 42% of the included patients were responders to NSAID
treatment. Notably, 39% of patients experienced side effects of NSAIDs.
In addition to the study and the case series, 2 case reports describing
treatment with NSAID were identified (Greenberg, 2014;Ray et al.,
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
60
2013). Greenberg et al. state that ibuprofen in addition to antibiotics
helped to speed improvement of psychiatric symptoms (Greenberg,
2014).
In the survey study (Calaprice et al., 2017), Ibuprofen was received
by 302 out of 698 included patients, with 23% reporting the treatment
to be “very effective”and 10% discontinuing due to lack of efficacy.
To conclude, NSAID has been described in one large case series, in
which 32 out of 77 patients were considered responders. One ob-
servational study (based on the same study population as the case
series) indicated that NSAID may shorten PANS flare duration. No trial
of NSAID has been conducted and therefore the overall evidence is
inconclusive.
4.2.7. Corticosteroids
One observational study evaluating the effect of corticosteroids on
flare duration in PANS was identified in the literature review (Brown
et al., 2017a). This study is also from the Stanford PANS clinic and the
study population is the first 178 consecutive patients of the clinic.
Ninety-eight patients, experiencing a total of 403 flares, who were
treated with oral corticosteroids were evaluated. Flares not treated with
corticosteroids (n = 318) had a mean duration of 11.4 weeks. Flares
treated with corticosteroids (n = 85) were shortened by 3.5 weeks
(95% CI −1.05 –5.95 weeks). Early treatment with oral corticosteroids
was associated with shorter flare duration. A longer treatment course
was associated with a longer duration of improvement. Side effects of
oral corticosteroids were reported in 44% of treatment courses, most
commonly escalation of psychiatric symptoms. Limitations include the
observational study design and non-blinded assessments.
In the survey study (Calaprice et al., 2017), 154 out of 698 patients
received short steroid tapers (< 14 days) with 49% considering this
treatment to be “very effective”and 7% discontining due to lack of
efficacy. Out of 72 patients who received treatment with long steroid
tapers (> 14 days), 54% considered their treatment as “very effective”
and 3% discontinued due to lack of efficacy.
A total of 15 patients who were treated with corticosteroids were
identified in the case reports (Allen et al., 1995;Chmelik et al., 2004;
Frankovich et al., 2015;Kovacevic et al., 2015;Kuluva et al., 2008). All
patients received corticosteroids in combination with several other
treatments. Ten of these individuals were included in a case series in
which successful treatments were observed with combined IVIG and
corticosteroids (Kovacevic et al., 2015). In another case report, OCD
developed as a possible side effect of prednisolone treatment (Chmelik
et al., 2004). An initial beneficial effect of prednisolone treatment was
reported in 1 patient; however, this treatment was ineffective when
symptoms later recurred (Allen et al., 1995).
Treatment with corticosteroids has been described in multiple case
reports and case series. Half of the treated patients in the survey study
reported corticosteroids as “very effective”. One observational study
indicated that PANS flares may be shortened by corticosteroids, but the
treatment has not been studied in a controlled setting. Notably, several
studies report escalation of psychiatric symptoms as side effects. To
conclude, the evidence for corticosteroids as treatment of PANS is in-
conclusive.
4.2.8. Selective serotonin reuptake inhibitors
In the self-reported survey study 265 patients had been treated with
SSRIs (Calaprice et al., 2017). 17% reported SSRIs to be “very effec-
tive”, 20% discontinued due to lack of efficacy and another 25% dis-
continued due lack of tolerability.
SSRIs have not been studied systematically in PANS, PANDAS,
CANS, or PITAND. However, treatments with SSRIs were reported in
case reports of 29 patients with PANDAS (Alexander et al., 2011;
Baytunca et al., 2016;Becker et al., 2004;Bodner et al., 2001;Calkin
and Carandang, 2007;Celik et al., 2016;Chmelik et al., 2004;Coffey
and Wieland, 2007;Das and Radhakrishnan, 2012;Doshi et al., 2015;
Fonseca et al., 2010;Gabbay and Coffey, 2003;Giedd et al., 1996;
Hachiya et al., 2013;Heubi and Shott, 2003;Kovacevic et al., 2015;
Kerbeshian et al., 2007;Kuluva et al., 2008;Lawrence and Baggott,
2017;Maini et al., 2012;Murphy et al., 2006;Navkhare and Kalra,
2014;Ray et al., 2013;Sadhasivam and Litman, 2006;
Sankaranarayanan and John, 2003;Sharma et al., 2012;Sokol, 2000;
Srivastava et al., 2012), 2 patients with PANS (Greenberg, 2014;
Ayaydin and Abali, 2010), and 1 patient with PITAND (Allen et al.,
1995). For 7 patients, the disorder was unimproved with SSRIs but
improved with antibiotics or immunomodulatory treatments (Celik
et al., 2016;Das and Radhakrishnan, 2012;Greenberg, 2014;Heubi and
Shott, 2003;Lawrence and Baggott, 2017;Navkhare and Kalra, 2014;
Sadhasivam and Litman, 2006). Three of the 29 patients experienced
paradoxical reactions from SSRIs (Calkin and Carandang, 2007;Maini
et al., 2012;Murphy et al., 2006). For 1 of these patients, a therapeutic
effect was achieved when the dosage of SSRIs was considerably lowered
(Murphy et al., 2006). A total of 9 patients were treated successfully
with SSRIs (Baytunca et al., 2016;Chmelik et al., 2004;Doshi et al.,
2015;Fonseca et al., 2010;Giedd et al., 1996;Ray et al., 2013;Sharma
et al., 2012;Srivastava et al., 2012). In all of these case reports, patients
received SSRIs in combination with other psychotropic or im-
munomodulatory medications. SSRIs have not been tested for PANS or
PANDAS in a controlled setting. Therefore, conclusions cannot be
drawn regarding the efficacy of SSRIs alone in these patients. However,
SSRIs are evidence based treatments for OCD, therefore positive out-
comes on OCD are expected and thus unlikely to be published as case
reports. It is also possible that treatment response from SSRIs can be
generalized to PANDAS and PANS presenting with OCD.
4.2.9. Other treatments
In the self-reported survey study on PANS (Calaprice et al., 2017),
psychotropic medication such as non-SSRI-antidepressants (n = 60),
ADHD medication (n = 114), antipsychotics (n = 95), anxiolytics
(n = 84) and mood-stabilizers (n = 63) were reported. Furthermore,
352 patients reported improvement from complementary and alter-
native medicine treatments, including probiotics, Omega 3, vitamin D,
homeopathy and gluten free diet.
In a series of 5 complex cases treated at a PANS clinic at Stanford
University, 1 patient with severe PANS was successfully treated with
monoclonal CD-20 antibody (rituximab) in combination with TPE
(Frankovich et al., 2015).
Many treatments of patients with PANDAS and related conditions
were given based on specific indications of the patient (e.g., treatment
for vitamin D deficiency) (Celik et al., 2016). In 1 case series in which
the treatment strategy was to cure sinusitis and thereby alleviate
PANDAS, all patients received antibiotics, and 3 patients also were
treated with sinus surgery. Upon remission of sinusitis, 8 of 10 patients
had improvement in psychiatric symptoms (Mahony et al., 2017). In
another case report, authors observed spontaneous remission of
PANDAS symptoms in absence of treatment (Cengel-Kultur et al.,
2009). In total, 26 case reports reported treatment with non-SSRI psy-
chotropic medications, including benzodiazepines, haloperidol, and
atomoxetine. All patients received additional treatments and/or sur-
gical procedures (e.g., SSRIs, antibiotics, steroids, CBT and tonsil-
lectomy) in combination with these psychotropic therapies. A full
summary of all case reports is presented in Supplementary Table S1.
5. Discussion
In this systematic review of articles published during a 17-year
period that addressed treatments for PANS, PANDAS, CANS, and
PITAND we identified only 4 RCTs, 1 cross-over study, 2 open trials, 4
observational studies and one survey study. We also identified 65 case
reports and case series that encompassed a total of 240 patients. No
authors used the diagnostic entity CANS, and only 7 case reports (Allen
et al., 1995;Ercan et al., 2008;Sokol and Gray, 1997) used the diag-
nostic criteria for PITAND to diagnose patients.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
61
Therapies that have been systematically studied for PANDAS and
PANS are antibiotics, IVIG, TPE, tonsillectomy, CBT, NSAID and corti-
costeroids. The studies are few and in general have moderate or high
risk of bias. The bulk of the published evidence is case reports and case
series. Using traditional methods of determining the evidence, there is
currently insufficient evidence to clearly propose any treatment for
PANDAS and related disorders. Nevertheless, there are 3 recent papers
proposing guidelines for how to treat PANDAS and PANS using psy-
chiatric and behavioral interventions (Thienemann et al., 2017), im-
munomodulatory therapies (Frankovich et al., 2017) and antibiotics
(Cooperstock et al., 2017). These guidelines are proposed by a con-
sortium of clinicians and researchers, and propose use of these 3 ther-
apeutic approaches for children who fulfill criteria for PANDAS or
PANS. We believe that our results are in line with the proposed
guidelines, and that the lack of evidence for treatment is based not on
the inefficacy of the treatments, but on lack of systematic research. This
being said, there is clearly need for more high quality research to de-
termine if and which treatment approaches are beneficial for patients
fulfilling criteria for PANDAS and PANS.
5.1. Methodological issues in the included articles
Several of the studies included patients receiving off-protocol study
medication, which makes it difficult to conclude an effect of the in-
vestigated treatment. In 2 of the studies on antibiotics, adjustments of
the drug dosage were permitted (Garvey et al., 1999;Snider et al.,
2005), and in 1 of these (Snider et al., 2005), off-study antibiotics were
prescribed for treatment of GABHS infection. In 1 of the tonsillectomy
studies (Pavone et al., 2014), IVIG was given to 8 patients, and anti-
biotics were given to several patients –apart from tonsillectomy.
Moreover, open-label IVIG was provided in 2 studies after the blinded
phase (Perlmutter et al., 1999;Williams et al., 2016). In the survey
study, a majority of the patients received multiple treatments, yet the
outcomes are reported on a treatment-by-treatment basis (Calaprice
et al., 2017). Because patients with PANDAS and related conditions
present with severe and acute psychiatric symptoms and infections, the
use of off-study medications was deemed necessary. Symptomatic
streptococcal infections are painful and can cause sequelae; these in-
fections should be treated if detected. The same is true with severe
psychiatric symptoms, which may require high doses of psychotropic
medication and result in long-term psychosocial impairment.
The episodic course of PANDAS and related disorders also compli-
cates these studies (Swedo et al., 1998). Treatment effects are difficult
to interpret in the context of a relapsing-remitting course and absence
of a control or placebo group. If the disorder enters a remitting phase
coinciding with the beginning of treatment, the treatment effect could
be overestimated.
Relevance of the outcome measures also should be considered. The
main criterion for PANDAS, PANS, CANS, and PITAND is the abrupt
nature of onset of OCD, tics, or an eating disorder. Treatment outcomes
for OCD typically are measured as change in score on the Yale-Brown
Obsessive Compulsive Scale (Y-BOCS; CY-BOCS for children) (Goodman
et al., 1989;Scahill et al., 1997). The Y-BOCS ranges from 0 to 40
points, with a higher score indicating more severe symptoms. The cutoff
for clinically important OCD is 16 points. A significant effect of treat-
ment for OCD is defined as a 35% reduction in Y-BOCS score combined
with a Clinical Global Impression Improvement (CGI-I) score of 1 or 2
(i.e., very much improved or much improved) (Mataix-Cols et al.,
2016). These outcome measures were used in several studies included
in this review (Garvey et al., 1999;Murphy et al., 2013;Murphy et al.,
2017;Nadeau et al., 2015;Pavone et al., 2014;Perlmutter et al., 1999;
Storch et al., 2006;Williams et al., 2016).
In addition to OCD and tics, the proposed diagnostic criteria for
PANDAS and related disorders also include a level of disease severity
and the presence of multiple other symptoms, such as violent behavior,
anxiety, hyperactivity, psychotic symptoms, motor problems, cognitive
decline, separation anxiety, and impaired overall function. The com-
bination of severe symptoms and sudden onset is thought to differ-
entiate these disorders from non-PANDAS OCD and Tourette syndrome.
However, in the studies and case reports analyzed herein, the outcome
measure typically is limited to obsessive-compulsive symptoms mea-
sured on the CY-BOCS. By this rubric, if a treatment results in remission
of compulsions –but aggravation of anxiety or psychotic symptoms –
the patient would be defined as a treatment responder. Thus, the in-
terpretation of treatment response in multiple-dimension disorders can
be confounded when a single-dimension outcome measure is applied. In
2 of the reviewed studies involving penicillin prophylaxis, psychiatric
exacerbations were the main outcome measure (Snider et al., 2005;
Garvey et al., 1999). In the two studies by Brown et al. (2017a,bthe
primary outcome measure was duration of symptom flares, which is
also in line with PANS and PANDAS diagnostic criteria. The flares
evaluated in the studies by Brown et al. include not only OCD, but all
psychiatric symptoms, and therefore this is a suitable outcome measure
when evaluating treatments for PANS and PANDAS. A combined out-
come measure that includes exacerbation onset and duration, target
symptoms, and global function may be needed to assess treatment re-
sponse adequately. The development of credible outcome measures is a
current challenge in the field of sudden-onset neuropsychiatric dis-
orders with proposed autoimmune etiology.
5.2. Non-PANDAS OCD
In the review process, we identified 2 treatment studies of anti-
biotics and TPE for non-PANDAS OCD (Murphy et al., 2015;Nicolson
et al., 2000) These studies did not meet inclusion criteria, but they are
relevant to this discussion. In a study by Murphy et al. (2015), treat-
ment with antibiotics (cefdinir) was compared to placebo for recent
onset OCD (not fulfilling PANS or PANDAS criteria) in 19 patients. No
significant between-group difference in treatment effect was found,
possibly owing to the small sample size. Nevertheless, there were in-
dications in this study that cefdinir may ameliorate non-PANDAS OCD
and tics, and further research involving larger sample sizes is needed to
determine this effect.
In a second study, TPE was given to 5 treatment-refractory patients
with non-PANDAS OCD (Nicolson et al., 2000). These patients had no
history of exacerbations related to streptococcal infections. No patient
experienced an improvement after 4 weeks. The lack of an effect was
interpreted as an indication of non–immune-related OCD. However,
this has not been studied further.
5.3. Adverse events
Most of the adverse events reported in the articles reviewed herein
were mild to moderate (e.g., nausea, vomiting, headache, and sto-
machache). Thus, potential benefits of the treatments usually exceeded
the occasional negative effects. Treatments with antibiotics, corticos-
teroids, IVIG, or TPE may be less harmful than antipsychotic drug
treatments, which often are prescribed in severe cases of OCD and
psychosis and for children who present aggressive behaviors –symp-
toms that are common in PANDAS and PANS. Notably, 3 case reports
and 10 patients in the survey study reported paradoxical effects of SSRIs
(Calaprice et al., 2017;Calkin and Carandang, 2007;Maini et al., 2012;
Murphy et al., 2006), which is in line with previous reports (Murphy
et al., 2006;Swedo et al., 2012).
5.4. Limitations and methodological discussion
We attempted to collect all available literature describing treatment
outcomes of patients with PANDAS, PANS, CANS, and PITAND. The
initial screening of 1087 abstracts was made by 2 investigators (E.H.
and S.S.), but all abstracts were not read by both individuals. In the
Scopus search, we used the filter “document type: article,”and this may
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
62
have led to some case reports being missed. The full-text review of 162
articles and extraction of data from 77 articles that met inclusion cri-
teria were carried out by both investigators, reading all articles. Our
goal was to obtain a complete data set; therefore, we included all ar-
ticles that had been identified by at least 1 of the authors as containing
data from a case report. However, we excluded articles that were not in
English, which eliminated articles in Swedish (Bejerot et al., 2013),
German (Schubert et al., 2006), Spanish (Fernández Ibieta et al., 2005;
Morer and Massana, 2000), Italian (Ferrafiat et al., 2017), and Polish
(Brynska and Wolanczyk, 2004). Hence, the data described in this re-
view are not comprehensive.
To minimize the risk of missing relevant articles, we were liberal in
our evaluation, and all articles in which we thought a case report may be
involved were included in the full-text review, even if the study was not
defined in the abstract or title as a case report. We also included all cases
in which the authors stated that the diagnosis “may be”PANDAS, PANS,
CANS, or PITAND as well as studies with unclear use of diagnostic cri-
teria (Bodner et al., 2001;Boseley et al., 2007;Ceylan et al., 2011;Coffey
and Wieland, 2007;Gabbay and Coffey, 2003;Giedd et al., 1996;Kuluva
et al., 2008;Maguire et al., 2010;Martinelli et al., 2002;Navkhare and
Kalra, 2014;Sankaranarayanan and John, 2003;Sharma et al., 2012;
Vitaliti et al., 2014). We have also chosen to include a large survey study
of self-reported treatment outcome in a self-selected sample as one of the
systematic evaluations of treatments in this review (Calaprice et al.,
2017). Despite the inherent limitations of using a survey to study treat-
ment outcome, this study is the largest study of treatment outcome in
PANS. Our liberal inclusion strategy enabled us to conduct a more
complete review, but the permissive application of inclusion criteria
should be considered when interpreting our results.
5.5. Conclusions
Successful treatment of any medical disorder depends on careful
diagnostic workup, identification of pathogeneses, appropriate treat-
ment, and valid evaluation of response. In the field of PANDAS, PANS,
CANS, and PITAND, all of these steps are problematic. Our findings
indicate that there is no strong evidence to recommend treatment of
PANDAS, PANS, CANS, and PITAND with antibiotics, tonsillectomy,
immunomodulation, CBT, SSRIs, or neuroleptics. Nevertheless, in many
case reports, authors note remarkable improvement after treatment
with IVIG, antibiotics, and TPE and it is possible that flare duration may
be shortened by NSAID or corticosteroids.
In the era of personalized medicine, symptoms of PANDAS, PANS,
and PITAND and related disorders should be treated on a case-by-case
basis. Careful collection of etiological clues and treatment outcomes can
be beneficial to patients and the research field alike. While awaiting
valid and well-designed RCTs, treatment of PANDAS and PANS with
antibiotics, IVIG, TPE, and/or corticosteroids –in addition to SSRIs and
CBT–can be defended in clinical practice if treatment response can be
expected. For instance, the use of antibiotics and tonsillectomy may
prevent recurring strep infections (Burton et al., 2014), and treatments
with IVIG, TPE, NSAIDs, and corticosteroids should be considered in
cases with clinical evidence of neuroinflammation. Our findings should
encourage further evaluations of potential treatments for these dis-
abling disorders.
Acknowledgements
We would like to thank Liz Holmgren at the Medical library in
Örebro, for her help while conducting the database searches. This re-
search was funded by grants from the Swedish Research Council (523-
2011-3646) and by grants provided by the Stockholm County Council
(PPG projects 20130671 and 20150150). The funding sources had no
influence over the study design, collection or interpretation of data or
any other part of the research process. We have no conflicts of interest
to disclose.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.neubiorev.2018.01.
001.
References
Alexander, A.A., Patel, N.J., Southammakosane, C.A., et al., 2011. Pediatric autoimmune
neuropsychiatric disorders associated with streptococcal infections (PANDAS): an
indication for tonsillectomy. Int. J. Pediatr Otorhinolaryngol. 75 (June(6)), 872–873.
http://dx.doi.org/10.1016/j.ijporl.2011.03.006. PubMed PMID: 21466900.
Allen, A.J., Leonard, H.L., Swedo, S.E., 1995. Case study: a new infection-triggered, au-
toimmune subtype of pediatric OCD and Tourette's syndrome. J. Am. Acad. Child.
Adolesc. Psychiatry 34 (March (3)), 307–311. http://dx.doi.org/10.1097/00004583-
199503000-00015. PubMed PMID: 7896671.
Aron, A.M., Freeman, J.M., Carter, S., 1965. The natural history of sydenham's chorea.
review of the literature and long-term evaluation with emphasis on cardiac sequelae.
The Am. J. Med. 38 (January), 83–95 PubMed PMID: 14247294; Eng.
Ayaydin, H., Abali, O., 2010. Early antibiotic treatment in a child with PANDAS: a case
report. Noropsikiyatri Arsivi 47 (2), 169–170. http://dx.doi.org/10.4274/npa.5424.
Batuecas Caletrío, Á, Sánchez González, F., Santa Cruz Ruiz, S., et al., 2008. PANDAS
syndrome: A new tonsillectomy indication? Acta Otorrinolaringol. Esp. 59 (7),
362–363. http://dx.doi.org/10.1016/S0001-6519(08)75557-2.
Baytunca, M.B., Donuk, T., Erermis, S., 2016. Evaluation of a neuropsychiatric disorder:
from PANDAS to PANS and CANS. Turk. Psikiyatri Derg 27 (Summer (2)) PubMed
PMID: 27370066.
Becker, K., Holtmann, M., El-Faddagh, M., et al., 2004. Separation anxiety triggered by
atypical neuroleptic medication in an adolescent with Tourette's syndrome. Clinical
Child Psychology Psychiatry. 9 (4), 597–603. http://dx.doi.org/10.1177/
1359104504046163.
Bejerot, S., Bruno, K., Gerland, G., et al., 2013. Misstänk PANDAS hos barn med akuta
neuropsykiatriska symtom infektion bakom sjukdomen - Långvarig anti-
biotikabehandling bör övervägas. Lakartidningen 110 (41), 1803.
Beşiroǧlu, L., Aǧargün, M.Y., Ozbebit, O., et al., 2007. Therapeutic response to plasma-
pheresis in four cases with obsessive-compulsive disorder and tic disorder triggered
by streptococcal infections. Türk psikiyatri dergisi Turk. J. Psychiatry 18 (3),
270–276.
Bodner, S.M., Morshed, S.A., Peterson, B.S., 2001. The question of PANDAS in adults.
Biol. Psychiatry 49 (May (9)), 807–810 PubMed PMID: 11331090.
Boseley, M.E., Gherson, S., Hartnick, C.J., 2007. Spasmodic dysphonia in an adolescent
patient with an autoimmune neurologic disorder. Am. J. Otolaryngol. 28
(March–April (2)), 140–142. http://dx.doi.org/10.1016/j.amjoto.2007.01.002.
PubMed PMID: 17362824.
Brown, K., Farmer, C., Farhadian, B., et al., 2017a. Pediatric acute-onset neuropsychiatric
syndrome response to Oral corticosteroid bursts: an observational study of patients in
an academic community-based PANS clinic. J. Child. Adolesc. Psychopharmacol.
http://dx.doi.org/10.1089/cap.2016.0139.
Brown, K.D., Farmer, C., Freeman, G.M., et al., 2017b. Effect of early and prophylactic
nonsteroidal anti-inflammatory drugs on flare duration in pediatric acute-onset
neuropsychiatric syndrome: an observational study of patients followed by an aca-
demic community-based pediatric acute-onset neuropsychiatric syndrome clinic. J.
Child. Adolesc. Psychopharmacol. http://dx.doi.org/10.1089/cap.2016.0193.
Browne, H.A., Hansen, S.N., Buxbaum, J.D., et al., 2015. Familial clustering of tic dis-
orders and obsessive-compulsive disorder. JAMA Psychiatry. 72 (Aprail (4)),
359–366. http://dx.doi.org/10.1001/jamapsychiatry.2014.2656. PubMed PMID:
25692669.
Brynska, A., Wolanczyk, T., 2004. Pediatric autoimmune neuropsychiatric disorders as-
sociated with streptococcal infections (PANDAS). A report of two cases. Psychiatr Pol.
38 (January–February (1)), 105–123 PubMed PMID: 15042736.
Burton, M.J., Glasziou, P.P., Chong, L.Y., et al., 2014. Tonsillectomy or adeno-
tonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis.
Cochrane Database Syst. Rev. 19 (November (11)), CD001802. http://dx.doi.org/10.
1002/14651858.CD001802.pub3. PubMed PMID: 25407135.
Calaprice, D., Tona, J., Murphy, T.K., 2017. Treatment of pediatric acute-onset neu-
ropsychiatric disorder in a large survey population. J. Child Adolesc.
Psychopharmacol.(August). http://dx.doi.org/10.1089/cap.2017.0101. PubMed
PMID: 28832181; eng.
Calkin, C.V., Carandang, C.G., 2007. Certain eating disorders may be a neuropsychiatric
manifestation of PANDAS: case report. J. Can. Acad. Child. Adolesc. Psychiatry. 16
(3), 132–135.
Celik, G., Tas, D.A., Varmis, D.A., et al., 2016. Vitamin D insufficiency in a boy with
obsessive-compulsive disorder. Pediatr Int. 58 (July (7)), 646–648. http://dx.doi.org/
10.1111/ped.12941. PubMed PMID: 27388777.
Cengel-Kultur, S.E., Cop, E., Kara, A., et al., 2009. The relationship between group A beta
hemolytic streptococcal infection and psychiatric symptoms: a pilot study. Turk. J.
Pediatr. 51 (July–August (4)), 317–324 PubMed PMID: 19950837.
Ceylan, M.F., Selek, S., Zeytinci, E., et al., 2011. A case of myoclonic symptoms after
streptococcal infection: possible PANDAS variant. Noropsikiyatri Ars 48 (1), 85–87.
http://dx.doi.org/10.4274/npa.y5614. PubMed PMID: WOS:000289561900016;
English.
Chiarello, F., Spitoni, S., Hollander, E., et al., 2017. An expert opinion on PANDAS/PANS:
highlights and controversies. Int. J. Psychiatry Clin. Pract. 21 (Junuary (2)), 91–98.
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
63
http://dx.doi.org/10.1080/13651501.2017.1285941. PubMed PMID: 28498087.
Chmelik, E., Awadallah, N., Hadi, F.S., et al., 2004. Varied presentation of PANDAS: a
case series. Clin. Pediatrics 43 (4), 379–382. http://dx.doi.org/10.1177/
000992280404300410.
Coffey, B., Wieland, N., 2007. Tics, anxiety, and possible PANDAS in an adolescent. J.
Child Adolesc. Psychopharmacol. 17 (August (4)), 533–538. http://dx.doi.org/10.
1089/cap.2007.17403. PubMed PMID: 17822348.
Cooperstock, M.S., Swedo, S.E., Pasternack, M.S., et al., 2017. Clinical management of
pediatric acute-onset neuropsychiatric syndrome: Part III—Treatment and prevention
of infections. J. Child. Adolesc. Psychopharmacol. http://dx.doi.org/10.1089/cap.
2016.0151.
Das, A., Radhakrishnan, A., 2012. A case of PANDAS with kleine-Levin type periodic
hypersomnia. Sleep Med. 13 (March (3)), 319–320. http://dx.doi.org/10.1016/j.
sleep.2011.11.003. PubMed PMID: 22261244.
Demesh, D., Virbalas, J.M., Bent, J.P., 2015. The role of tonsillectomy in the treatment of
pediatric autoimmune neuropsychiatric disorders associated with streptococcal in-
fections (PANDAS). JAMA Otolaryngol. Head Neck Surg. 141 (March (3)), 272–275.
http://dx.doi.org/10.1001/jamaoto.2014.3407. PubMed PMID: 25569020.
do Rosario-Campos, M.C., Leckman, J.F., Curi, M., et al., 2005. A family study of early-
onset obsessive-compulsive disorder. Ame J. Med. Genet. Part B, Neuropsychiatr.
Genet. 136b (July (1)), 92–97. http://dx.doi.org/10.1002/ajmg.b.30149. PubMed
PMID: 15892140; eng.
Doshi, S., Maniar, R., Banwari, G., 2015. Pediatric autoimmune neuropsychiatric dis-
orders associated with streptococcal infections (PANDAS). Indian J. Pediatr. 82 (May
(5)), 480–481. http://dx.doi.org/10.1007/s12098-014-1641-y. PubMed PMID:
25502585.
Elia, J., Dell, M.L., Friedman, D.F., et al., 2005. PANDAS with catatonia: A case report.
therapeutic response to lorazepam and plasmapheresis. J. Am. Acad. Child Adolesc.
Psychiatry. 44 (11), 1145–1150. http://dx.doi.org/10.1097/01.chi.0000179056.
54419.5e.
Ercan, E.T., Ercan, G., Severge, B., et al., 2008. Mycoplasma pneumoniae infection and
obsessive-compulsive disease: A case report. J. Child. Neurology. 23 (3), 338–340.
http://dx.doi.org/10.1177/0883073807308714.
Fernández Ibieta, M., Ramos Amador, J.T., Auñón Martín, I., et al., 2005.
Neuropsychiatric disorders associated with streptococci: a case report. Anales de
Pediatria. 62 (5), 475–478. http://dx.doi.org/10.1157/13074623.
Ferrafiat, V., Raffin, M., Gianniteli, M., et al., 2017. Autoimmune disorders and psychiatry
in youth. Neuropsychiatrie de l'Enfance et de l'Adolescence. 65 (2), 99–109. http://
dx.doi.org/10.1016/j.neurenf.2017.01.005.
Fonseca, L., Guerra, J., Neves, N., et al., 2010. PANDAS (pediatric autoimmune neu-
ropsychiatric disorders associated with streptococcal infection): a case report. J.
Neuropsychiatry Clin. Neurosci. 22 (Summer (3)). http://dx.doi.org/10.1176/appi.
neuropsych.22.3.352-f.e9. 352f e9-e10, PubMed PMID: 20686150.
Frankovich, J., Thienemann, M., Rana, S., et al., 2015. Five youth with pediatric acute-
onset neuropsychiatric syndrome of differing etiologies. J. Child Adolesc.
Psychopharmacol. 25 (February (1)), 31–37. http://dx.doi.org/10.1089/cap.2014.
0056. PubMed PMID: 25695942; PubMed Central PMCID: PMCPMC4442568.
Frankovich, J., Swedo, S., Murphy, T., et al., 2017. Clinical management of pediatric
acute-onset neuropsychiatric syndrome: Part II—use of immunomodulatory thera-
pies. J. Child. Adolesc. Psychopharmacol. http://dx.doi.org/10.1089/cap.2016.0148.
Fusco, F.R., Pompa, A., Bernardi, G., et al., 2010. A case of PANDAS treated with tetra-
benazine and tonsillectomy. J. Child Neurol. 25 (May (5)), 614–615. http://dx.doi.
org/10.1177/0883073809355824. PubMed PMID: 20207613.
Gabbay, V., Coffey, B., 2003. Obsessive-compulsive disorder, Tourette's disorder, or pe-
diatric autoimmune neuropsychiatric disorders associated with streptococcus in an
adolescent? diagnostic and therapeutic challenges. J. Child Adolesc.
Psychopharmacol. 13 (Fall (3)), 209–212. http://dx.doi.org/10.1089/
104454603322572516. PubMed PMID: 14642008.
Garvey, M.A., Perlmutter, S.J., Allen, A.J., et al., 1999. A pilot study of penicillin pro-
phylaxis for neuropsychiatric exacerbations triggered by streptococcal infections.
Biol. Psychiatry 45 (January (12)), 1564–1571 PubMed PMID: 10376116.
Gerardi, D.M., Casadonte, J., Patel, P., et al., 2015. PANDAS and comorbid kleine-levin
syndrome. J. Child Adolesc. Psychopharmacol. 25 (February (1)), 93–98. http://dx.
doi.org/10.1089/cap.2014.0064. PubMed PMID: 25329605; PubMed Central PMCID:
PMCPMC4340647.
Giedd, J.N., Rapoport, J.L., Kruesi, M.J., et al., 1995. Sydenham’s chorea: magnetic re-
sonance imaging of the basal ganglia. Neurology 45 (December (12)), 2199–2202
PubMed PMID: 8848193; Eng.
Giedd, J.N., Rapoport, J.L., Leonard, H.L., et al., 1996. Case study: acute basal ganglia
enlargement and obsessive-compulsive symptoms in an adolescent boy. J. Am. Acad.
Child. Adolesc. Psychiatry 35 (July (7)), 913–915. http://dx.doi.org/10.1097/
00004583-199607000-00017. PubMed PMID: 8768351.
Goodman, W.K., Price, L.H., Rasmussen, S.A., et al., 1989. The Yale-Brown obsessive
compulsive scale. I. development, use, and reliability. Arch. Gen. Psychiatry 46 (11),
1006–1011.
Grant, J.E., 2014. Clinical practice: obsessive-compulsive disorder. N. Engl. J. Med. 371
(August (7)), 646–653. http://dx.doi.org/10.1056/NEJMcp1402176. PubMed PMID:
25119610.
Greenberg, R., 2014. Pediatric autoimmune neuropsychiatric disorders associated with
streptococcal infections/pediatric acute-onset neuropsychiatric syndromes vs. pe-
diatric bipolar disorder - a possible connection? Neurol. Psychiatry Brain Res. 20 (3),
49–54. http://dx.doi.org/10.1016/j.npbr.2014.06.004.
Guy, W., ECDEU, 1976. Assessment Manual for Psychopharmacology —Revised (DHEW
Publ No ADM. Department of Health, Education, and Welfare, Rockville, MD: U.S, pp.
76–338.
Hachiya, Y., Miyata, R., Tanuma, N., et al., 2013. Autoimmune neurological disorders
associated with group-A beta-hemolytic streptococcal infection. Brain Dev. 35
(August (7)), 670–674. http://dx.doi.org/10.1016/j.braindev.2012.10.003. PubMed
PMID: 23142103.
Heubi, C., Shott, S.R., 2003. PANDAS: pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections–an uncommon, but important indication for
tonsillectomy. Int. J Pediatr Otorhinolaryngol. 67 (August (8)), 837–840 PubMed
PMID: 12880661.
Hollis, C., Pennant, M., Cuenca, J., et al., 2016. Clinical effectiveness and patient per-
spectives of different treatment strategies for tics in children and adolescents with
tourette syndrome: a systematic review and qualitative analysis. Health Technol.
Assess. 20 (4). http://dx.doi.org/10.3310/hta20040.
Husby, G., van de Rijn, I., Zabriskie, J.B., et al., 1976. Antibodies reacting with cytoplasm
of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J.
Exp. Med. 144 (October (4)), 1094–1110 PubMed PMID: 789810; PubMed Central
PMCID: PMCPMC2190435. Eng.
Kerbeshian, J., Burd, L., Tait, A., 2007. Chain reaction or time bomb: A neuropsychiatric-
developmental/neurodevelopmental formulation of tourettisms, pervasive develop-
mental disorder, and schizophreniform symptomatology associated with PANDAS.
World J. Biol. Psychiatry. 8 (3), 201–207. http://dx.doi.org/10.1080/
15622970601182652.
Kovacevic, M., Grant, P., Swedo, S.E., 2015. Use of intravenous immunoglobulin in the
treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections. J. Child Adolesc. Psychopharmacol. 25
(February(1)), 65–69. http://dx.doi.org/10.1089/cap.2014.0067. PubMed PMID:
25658609; PubMed Central PMCID: PMCPMC4340809.
Kuluva, J., Hirsch, S., Coffey, B., 2008. PANDAS and paroxysms: A case of conversion
disorder? J. Child Adolescent Psychopharmacol. 18 (1), 109–115. http://dx.doi.org/
10.1089/cap.2007.1813.
Latimer, M.E., L'Etoile, N., Seidlitz, J., et al., 2015. Therapeutic plasma apheresis as a
treatment for 35 severely ill children and adolescents with pediatric autoimmune
neuropsychiatric disorders associated with streptococcal infections. J. Child Adolesc.
Psychopharmacol. 25 (February (1)), 70–75. http://dx.doi.org/10.1089/cap.2014.
0080. PubMed PMID: 25658452; PubMed Central PMCID: PMCPMC4340509.
Lawrence, R., Baggott, J., 2017. Autoimmune neuropsychiatric disorders associated with
infection. Prog. Neurol. Psychiatry 21 (1), 26–29. http://dx.doi.org/10.1002/pnp.
460.
Lynch, N.E., Deiratany, S., Webb, D.W., et al., 2006. PANDAS (paediatric autoimmune
neuropsychiatric disorder associated with Streptococcal infection). Iran Med. J. 100
(1), 155.
Maguire, G.A., Viele, S.N., Agarwal, S., et al., 2010. Stuttering onset associated with
streptococcal infection: a case suggesting stuttering as PANDAS. Ann. Clin.
Psychiatry. 22 (November (4)), 283–284 PubMed PMID: 21180660.
Mahony, T., Sidell, D., Gans, H., et al., 2017. Improvement of psychiatric symptoms in
youth following resolution of sinusitis. Int. J. Pediatric Otorhinolaryngol. 92, 38–44.
http://dx.doi.org/10.1016/j.ijporl.2016.10.034.
Maini, B., Bathla, M., Dhanjal, G.S., et al., 2012. Pediatric autoimmune neuropsychiatric
disorders after streptococcus infection. Indian J. Psychiatry. 54 (October (4)),
375–377. http://dx.doi.org/10.4103/0019-5545.104827. PubMed PMID: 23372243;
PubMed Central PMCID: PMCPMC3554972.
Martinelli, P., Ambrosetto, G., Minguzzi, E., et al., 2002. Late-onset PANDAS syndrome
with abdominal muscle involvement. European Neurology. 48 (1), 49–51. http://dx.
doi.org/10.1159/000064960.
Mataix-Cols, D., Fernandez de la Cruz, L., Nordsletten, A.E., et al., 2016. Towards an
international expert consensus for defining treatment response, remission, recovery
and relapse in obsessive-compulsive disorder. World Psychiatry 15 (February (1)),
80–81. http://dx.doi.org/10.1002/wps.20299. PubMed PMID: 26833615; PubMed
Central PMCID: PMCPMC4780290.
Moher, D., Liberati, A., Tetzlaff, J., et al., 2009. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. BMJ. 21 (July (339)), b2535.
http://dx.doi.org/10.1136/bmj.b2535. PubMed PMID: 19622551; PubMed Central
PMCID: PMCPMC2714657.
Morer, A., Massana, J., 2000. Alteraciones inmunológicas asociadas a tics, TOC y
PANDAS. Med. Clin. 114 (17), 665–668.
Muir, K.E., McKenney, K.S., Connolly, M.B., et al., 2013. A case report of obsessive-
compulsive disorder following acute disseminated encephalomyelitis. Pediatrics 132
(3), e771–e774. http://dx.doi.org/10.1542/peds.2012-2876.
Murphy, M.L., Pichichero, M.E., 2002. Prospective identification and treatment of chil-
dren with pediatric autoimmune neuropsychiatric disorder associated with group A
streptococcal infection (PANDAS). Arch. Pediatr. Adolesc. Med. 156 (4), 356–361.
Murphy, T.K., Storch, E.A., Strawser, M.S., 2006. Selective serotonin reuptake inhibitor-
induced behavioral activation in the PANDAS subtype. Prim. Psychiatry. 13 (8),
87–89.
Murphy, T.K., Lewin, A.B., Parker-Athill, E.C., et al., 2013. Tonsillectomies and adenoi-
dectomies do not prevent the onset of pediatric autoimmune neuropsychiatric dis-
order associated with group A streptococcus. Pediatr Infect. Dis. J. 32 (August (8)),
834–838. http://dx.doi.org/10.1097/INF.0b013e31829062e2. PubMed PMID:
23518825; PubMed Central PMCID: PMCPMC3740796.
Murphy, T.K., Gerardi, D.M., Leckman, J.F., 2014. Pediatric acute-onset neuropsychiatric
syndrome. Psychiatr Clin. North Am. 37 (September (3)), 353–374. http://dx.doi.
org/10.1016/j.psc.2014.06.001. PubMed PMID: 25150567.
Murphy, T.K., Parker-Athill, E.C., Lewin, A.B., et al., 2015. Cefdinir for recent-onset pe-
diatric neuropsychiatric disorders: A pilot randomized trial. J. Child
Adolesc.Psychopharmacol. 25 (1), 57–64. http://dx.doi.org/10.1089/cap.2014.
0010.
Murphy, T.K., Brennan, E.M., Johnco, C., et al., 2017. A double-blind randomized pla-
cebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-
S. Sigra et al. Neuroscience and Biobehavioral Reviews 86 (2018) 51–65
64
compulsive disorder. J. Child Adolesc. Psychopharmacol. 30 (March). http://dx.doi.
org/10.1089/cap.2016.0190. PubMed PMID: 28358599.
Nadeau, J.M., Jordan, C., Selles, R.R., et al., 2015. A pilot trial of cognitive-behavioral
therapy augmentation of antibiotic treatment in youth with pediatric acute-onset
neuropsychiatric syndrome-related obsessive-compulsive disorder. J. Child Adolesc.
Psychopharmacol. 25 (May(4)), 337–343. http://dx.doi.org/10.1089/cap.2014.
0149. PubMed PMID: 25978743; PubMed Central PMCID: PMCPMC4442557.
Navkhare, P., Kalra, G., 2014. The curious case of the inseparable child. Indian J.
Psychiatry 56 (July(3)), 292–294. http://dx.doi.org/10.4103/0019-5545.140650.
PubMed PMID: 25316942; PubMed Central PMCID: PMCPMC4181186.
Nicolson, R., Swedo, S.E., Lenane, M., et al., 2000. An open trial of plasma exchange in
childhood-onset obsessive-compulsive disorder without poststreptococcal exacerba-
tions. J. Am. Acad. Child Adolesc. Psychiatry 39 (10), 1313–1315.
Orlovska, S., Vestergaard, C.H., Bech, B.H., et al., 2017. Association of streptococcal
throat infection with mental disorders: testing key aspects of the PANDAS hypothesis
in a nationwide study. JAMA Psychiatry(May (24)). http://dx.doi.org/10.1001/
jamapsychiatry.2017.0995. PubMed PMID: